Anzeige
Mehr »
Samstag, 15.11.2025 - Börsentäglich über 12.000 News
Die KI-Comeback-Story des Jahres 2025
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 882361 | ISIN: US5898891040 | Ticker-Symbol: MM3
Tradegate
14.11.25 | 19:14
73,00 Euro
-0,68 % -0,50
1-Jahres-Chart
MERIT MEDICAL SYSTEMS INC Chart 1 Jahr
5-Tage-Chart
MERIT MEDICAL SYSTEMS INC 5-Tage-Chart
RealtimeGeldBriefZeit
72,5074,0013:04
72,5074,0014.11.

Aktuelle News zur MERIT MEDICAL SYSTEMS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrMerit Medical to launch Wrapsody endoprosthesis in U.S. after CMS defers reimbursement decision4
FrVerzögerung bei Wrapsody: Canaccord senkt Kursziel für Merit Medical auf 93 US-Dollar2
MERIT MEDICAL SYSTEMS Aktie jetzt für 0€ handeln
FrMerit Medical stock price target lowered to $93 at Canaccord on Wrapsody reimbursement delay1
DoMerit Medical withdraws application for Medicare payment boost2
DoMERIT MEDICAL SYSTEMS INC - 8-K, Current Report-
05.11.Merit Medical Systems, Inc.: Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial117The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty...
► Artikel lesen
03.11.Merit Medical Systems, Inc.: Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial127At 24 months, the target lesion primary patency (TLPP)1 was 41.7%At 24 months, the access circuit primary patency (ACPP)2 was 25.7% SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical...
► Artikel lesen
31.10.Merit Medical Q3 Earnings & Revenues Beat Estimate, Margins Expand1
31.10.Where Merit Medical Systems Stands With Analysts3
31.10.Merit Medical targets $175M free cash flow in 2025 with updated guidance and new CEO at helm1
30.10.Merit Medical Q3 2025 slides: Revenue jumps 13%, guidance raised1
30.10.Merit Medical Systems Inc Q3 Profit Decreases, But Beats Estimates-
30.10.MERIT MEDICAL SYSTEMS INC - 10-Q, Quarterly Report1
30.10.MERIT MEDICAL SYSTEMS INC - 8-K, Current Report1
29.10.Exploring Merit Medical Systems' Earnings Expectations3
16.10.Merit Medical to acquire cryoballoon tech from Pentax2
16.10.Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition1
16.10.Merit Medical Systems stock price target raised to $104 from $103 at Canaccord1
15.10.Merit Medical to acquire C2 CryoBalloon technology for $22M3
15.10.Merit Medical Systems To PENTAX Medical's C2 CryoBalloon Device And Related Technology6
Weiter >>
77 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1